Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]-
NF2 Deficiency
Ikena OncologySmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the NF2 Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Temsirolimus M.D. Anderson Cancer Center | Phase 1 | CC |
Cetuximab M.D. Anderson Cancer Center | Phase 1 | CC |
Valproic Acid M.D. Anderson Cancer Center | Phase 1 | CC |
Osimertinib Ikena Oncology | Phase 1 | CC |
st002 Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A | NR |
Same molecule, other indications
Benzenesulfonamide, N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →